

Necitumumab SQUIRE


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects




Other adjustments



Necitumumab SQUIRE

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Locally advanced or metastatic EGFR-expressing squamous NSCLC without prior ChT
Experimental Arm: Necitumumab + Gemcitabine + cisplatin
Control Arm: Gemcitabine + cisplatin

